These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

94 related articles for article (PubMed ID: 19670296)

  • 41. Gemifloxacin mesylate (GFM): dissolution test based on in vivo data.
    Paim CS; Verlindo de Araújo B; Volpato NM; Steppe M; Schapoval EE
    Drug Dev Ind Pharm; 2015 Apr; 41(4):567-72. PubMed ID: 24517572
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Serum bactericidal activity of gemifloxacin versus clarithromycin against Streptococcus pneumoniae with different susceptibility to quinolones.
    Malerczyk C; Kolbert M; Kinzig-Schippers M; Sörgel F; Machka K; Shah PM
    J Chemother; 2004 Feb; 16(1):56-61. PubMed ID: 15078000
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Comparison of different pharmacodynamic models for PK-PD modeling of verapamil in renovascular hypertension.
    Bertera FM; Mayer MA; Opezzo JA; Taira CA; Höcht C
    J Pharmacol Toxicol Methods; 2008; 57(3):212-9. PubMed ID: 18442930
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Fluoroquinolone resistance in Streptococcus pneumoniae: area under the concentration-time curve/MIC ratio and resistance development with gatifloxacin, gemifloxacin, levofloxacin, and moxifloxacin.
    LaPlante KL; Rybak MJ; Tsuji B; Lodise TP; Kaatz GW
    Antimicrob Agents Chemother; 2007 Apr; 51(4):1315-20. PubMed ID: 17296740
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Transport of gemifloxacin, a 4th generation quinolone antibiotic, in the Caco-2 and engineered MDCKII cells, and potential involvement of efflux transporters in the intestinal absorption of the drug.
    Jin HE; Song B; Kim SB; Shim WS; Kim DD; Chong S; Chung SJ; Shim CK
    Xenobiotica; 2013 Apr; 43(4):355-67. PubMed ID: 23020787
    [TBL] [Abstract][Full Text] [Related]  

  • 46. In vitro Dynamic Pharmacokinetic/Pharmacodynamic (PK/PD) study and COPD of Marbofloxacin against Haemophilus parasuis.
    Sun J; Xiao X; Huang RJ; Yang T; Chen Y; Fang X; Huang T; Zhou YF; Liu YH
    BMC Vet Res; 2015 Dec; 11():293. PubMed ID: 26626889
    [TBL] [Abstract][Full Text] [Related]  

  • 47. In vitro activity of gemifloxacin (SB-265805, LB20304a) against Legionella pneumophila and its pharmacokinetics in guinea pigs with L. pneumophila pneumonia.
    Edelstein PH; Shinzato T; Doyle E; Edelstein MA
    Antimicrob Agents Chemother; 2001 Aug; 45(8):2204-9. PubMed ID: 11451675
    [TBL] [Abstract][Full Text] [Related]  

  • 48. A new cause of acute hepatitis: gemifloxacin.
    Kilincalp S; Deveci M; Coban S; Basar O; Yuksel O
    Acta Gastroenterol Belg; 2012 Dec; 75(4):460-1. PubMed ID: 23402094
    [No Abstract]   [Full Text] [Related]  

  • 49. Norfloxacin-induced electroencephalogram alteration and seizures in rats are not triggered by enhanced levels of intracerebral glutamate.
    Chenel M; Limosin A; Marchand S; Paquereau J; Mimoz O; Couet W
    Antimicrob Agents Chemother; 2003 Nov; 47(11):3660-2. PubMed ID: 14576142
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Reversed phase liquid chromatography method with fluorescence detection of gemifloxacin in rat plasma and its application to the pharmacokinetic study.
    Kaiser M; Grünspan LD; Costa TD; Tasso L
    J Chromatogr B Analyt Technol Biomed Life Sci; 2011 Nov; 879(30):3639-44. PubMed ID: 21963480
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Pharmacokinetic-pharmacodynamic modeling of mivacurium in rats.
    Trocóniz IF; Garrido MJ; García E; Suárez E; Calvo R
    J Pharm Sci; 1997 Feb; 86(2):252-6. PubMed ID: 9040105
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Pharmacokinetic-pharmacodynamic modeling of the central nervous system effects of heptabarbital using aperiodic EEG analysis.
    Mandema JW; Danhof M
    J Pharmacokinet Biopharm; 1990 Oct; 18(5):459-81. PubMed ID: 1979991
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Ex vivo efficacy of gemifloxacin in experimental keratitis induced by methicillin-resistant Staphylococcus aureus.
    Marino A; Blanco AR; Ginestra G; Nostro A; Bisignano G
    Int J Antimicrob Agents; 2016 Oct; 48(4):395-400. PubMed ID: 27554440
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Challenges in assessing microbial susceptibility and predicting clinical response to newer-generation fluoroquinolones.
    Segreti J; Jones RN; Bertino JS
    J Ocul Pharmacol Ther; 2012 Feb; 28(1):3-11. PubMed ID: 21999341
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Lack of pharmacokinetic interaction between gemifloxacin and digoxin in healthy elderly volunteers.
    Vousden M; Allen A; Lewis A; Ehren N
    Chemotherapy; 1999; 45(6):485-90. PubMed ID: 10567779
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Pharmacodynamics: relation to antimicrobial resistance.
    Rybak MJ
    Am J Med; 2006 Jun; 119(6 Suppl 1):S37-44; discussion S62-70. PubMed ID: 16735150
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Pharmacokinetic-pharmacodynamic modeling of diltiazem in spontaneously hypertensive rats: a microdialysis study.
    Bertera FM; Mayer MA; Opezzo JA; Taira CA; Bramuglia GF; Höcht C
    J Pharmacol Toxicol Methods; 2007; 56(3):290-9. PubMed ID: 17560132
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Nociceptive stimulus modality-related difference in pharmacokinetic-pharmacodynamic modeling of morphine in the rat.
    Shang GW; Liu DN; Yan LH; Cui XY; Zhang KP; Qi C; Chen J
    Pharmacol Biochem Behav; 2006 Oct; 85(2):464-73. PubMed ID: 17126387
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Pharmacokinetic and pharmacodynamic testing of marbofloxacin administered as a single injection for the treatment of bovine respiratory disease.
    Vallé M; Schneider M; Galland D; Giboin H; Woehrlé F
    J Vet Pharmacol Ther; 2012 Dec; 35(6):519-28. PubMed ID: 22126438
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Evaluation of phototoxic potential of gemifloxacin in healthy volunteers compared with ciprofloxacin.
    Vousden M; Ferguson J; Richards J; Bird N; Allen A
    Chemotherapy; 1999; 45(6):512-20. PubMed ID: 10567783
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.